Omeros Corporation (OMER) Q2 2025 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good afternoon and welcome to today's earnings call for O'Meara's Corporation. At this time, all participants are on a listen-only mode. After the company's remarks, we will conduct a question and answer session. Please be advised this call is being recorded at the company's request and the replay will be available on the company's website one week from today. I will now turn the call over to Jennifer Williams, Investor Relations for O'Meara's. Good afternoon and thank you for joining us or sticking with us. Before we begin, I'd like to remind you that certain statements made during this call are for... These statements reflect management's current beliefs and expectations as of today and are subject to change. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially. For discussion of these risks and uncertainties, please refer to the special notes and the risk factors section regarding forward-looking statements in our quarterly report on Form 10-Q filed today with the SEC and the risk factors section of our most recent annual report on Form 10-K. With that, I'll turn the call over to Chairman and CEO of Omeros, Dr. Greg Dimopoulos. Thank you, Jennifer, and good afternoon, everyone. Joining me today are David Borges, our Chief Accounting Officer, Nadia Dock, Chief Commercial Officer, Dr. Andreas Grauer, Chief Medical Officer, Dr. Kathy Melfi, Chief Regulatory Officer, and Dr. Steve Whitaker, Vice President of Clinical. I'll begin with an overview of our second quarter 2025 financial results and provide updates across our development programs. David will then walk through the financials in more detail and will open the call for questions. Our net loss for the second quarter of 2025 was $25.4 million or 43 cents ...